TRCT
ALZN icon

Tower Research Capital (TRC)’s Alzamend Neuro ALZN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.22K Sell
3,517
-2,667
-43% -$2.96K ﹤0.01% 4418
2026
Q1 		$6.55K Buy
6,184
+4,103
+197% +$8.2K ﹤0.01% 4050
2025
Q4 		$3.79K Buy
2,081
+475
+30% +$1.08K ﹤0.01% 4313
2025
Q3 		$3.82K Buy
1,606
+809
+102% +$2.1K ﹤0.01% 4444
2025
Q2 		$2.32K Buy
+797
New +$3.95K ﹤0.01% 4667
2025
Q1 		– Sell
-43
Closed -$450 – 5153
2024
Q4 		$450 Sell
43
-420
-91% -$5.4K ﹤0.01% 5267
2024
Q3 		$7.04K Buy
463
+405
+698% +$10.6K ﹤0.01% 4083
2024
Q2 		$2.04K Buy
58
+5
+9% +$286 ﹤0.01% 5061
2024
Q1 		$4.75K Buy
53
+16
+43% +$1.37K ﹤0.01% 4637
2023
Q4 		$2.95K Buy
37
+1
+3% +$164 ﹤0.01% 5147
2023
Q3 		$11.5K Buy
36
+23
+177% +$11K ﹤0.01% 3985
2023
Q2 		$8.78K Sell
13
-9
-41% -$7.05K ﹤0.01% 4373
2023
Q1 		$12K Buy
22
+9
+69% +$6.77K ﹤0.01% 4044
2022
Q4 		$10K Buy
+13
New +$18.8K ﹤0.01% 3946
2022
Q3 		– Sell
-11
Closed -$13K – 6027
2022
Q2 		$13K Buy
11
+2
+22% +$2.59K ﹤0.01% 4192
2022
Q1 		$15K Buy
+9
New +$16.9K ﹤0.01% 3790
2021
Q4 		– Sell
-20
Closed -$82K – 6105
2021
Q3 		$82K Buy
20
+18
+900% +$98.9K ﹤0.01% 2562
2021
Q2 		$18K Buy
+2
New +$25.8K ﹤0.01% 3977

Other funds holding ALZN

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Tower Research Capital (TRC)'s ALZN Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Alzamend Neuro (ALZN) stake by 43% in Q2 2026, selling an estimated $2.96K and leaving 3,517 shares worth $4.22K. The position accounts for ﹤0.01% of the portfolio, ranked #4418.

Tower Research Capital (TRC) first reported a position in ALZN in Q2 2021 and has held it in 18 quarters since. The position peaked at $82K in Q3 2021. 12 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

  • Tower Research Capital (TRC) held 3,517 shares of Alzamend Neuro worth $4.22K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,667 Alzamend Neuro shares in Q2 2026, an estimated $2.96K.
  • Alzamend Neuro made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4418 holding.
  • Tower Research Capital (TRC) first reported a position in Alzamend Neuro in Q2 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Alzamend Neuro position peaked at $82K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.